Maternal Pertussis Vaccine for Newborn Protection Market

List of Tables

The Maternal Pertussis Vaccine for Newborn Protection Market is projected to grow by USD 3.42 billion at a CAGR of 6.79% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 2.15 billion
Estimated Year [2026]	USD 2.30 billion
Forecast Year [2032]	USD 3.42 billion
CAGR (%)	6.79%

Maternal Pertussis Vaccination as a Newborn Protection Strategy

Maternal pertussis vaccination is a prevention strategy designed to protect infants during the first months of life, before completion of their own primary immunization series. Vaccination during pregnancy can support transplacental transfer of antibodies and reduce the risk of severe pertussis in newborns. Program performance depends on clinical guidance, timely antenatal care, vaccine confidence, supply continuity, and effective referral and documentation systems.

Pregnancy Care Integration Is Reshaping Pertussis Prevention

The landscape is shifting from stand-alone immunization activity toward integration with routine antenatal services. This places greater emphasis on offering vaccination at the recommended stage of pregnancy, reducing missed opportunities, and ensuring consistent messages from obstetric, midwifery, primary-care, and public-health teams. Delivery models increasingly need to accommodate pharmacy-based services, community outreach, electronic reminders, and catch-up processes for people who begin prenatal care late.

Artificial Intelligence Can Improve Identification and Delivery Workflows

Artificial intelligence can support maternal pertussis vaccination without replacing clinical judgment. Potential applications include identifying patients who may be approaching the recommended vaccination window, flagging incomplete records, optimizing appointment outreach, translating educational materials, and detecting geographic or demographic gaps in uptake. Safe deployment requires validated data, privacy safeguards, bias monitoring, clinician oversight, and clear separation between decision support and autonomous medical advice.

Regional Priorities Differ Across Maternal Immunization Systems

In North America, priorities include maintaining strong prenatal-provider recommendations, improving access for underserved communities, and linking maternal vaccination records across care settings. Latin America may benefit from integration with public antenatal programs, community health networks, and trusted local communication channels. Europe faces the need to align national schedules and sustain confidence across diverse health systems. The Middle East can strengthen delivery through maternity hospitals, primary-care networks, and culturally appropriate counseling. Africa requires attention to antenatal attendance, cold-chain reliability, workforce capacity, and equitable rural access. Asia-Pacific presents varied needs, including urban-rural coverage gaps, fragmented records, and coordination between public and private maternity services.

Multilateral Groups Can Coordinate Standards, Access, and Confidence

ASEAN cooperation can support shared training, cross-border learning, and consistent maternal-immunization communication. BRICS members can exchange approaches to domestic production, procurement resilience, surveillance, and delivery through large public-health systems. The European Union can advance interoperability, evidence communication, and alignment while respecting national program decisions. G7 members can contribute to evidence generation, safety monitoring, and support for resilient supply and implementation systems. GCC countries can leverage integrated hospital networks and coordinated prenatal care pathways. NATO members may strengthen continuity planning and health-system preparedness, particularly where vaccination delivery depends on resilient logistics and interoperable records.

Country Programs Require Context-Specific Implementation Priorities

Australia can focus on consistent antenatal recommendations across public and private providers. Brazil and Mexico can strengthen outreach through primary care and community-based prenatal services. Canada, the United States, the United Kingdom, France, Germany, Italy, and Spain can prioritize equitable access, standardized provider prompts, and accurate recording across fragmented care settings. China and India may benefit from stronger integration between maternal health services and immunization registries, with attention to regional variation. Japan and South Korea can emphasize trusted clinician communication and coordinated prenatal scheduling. Russia can focus on consistent clinical guidance, surveillance, and access across geographically diverse regions.

Leaders Should Embed Vaccination Into Every Eligible Antenatal Encounter

Industry and health-system leaders should establish clear pregnancy-specific protocols, train all relevant prenatal-care staff, and use standing referral or reminder workflows to reduce missed opportunities. They should monitor timeliness, completion, access by population group, adverse-event reporting, and documentation quality rather than relying on procurement or appointment counts alone. Partnerships with maternity facilities, pharmacies, community organizations, and digital-health providers can extend reach, while transparent safety communication and rapid response to misinformation can reinforce confidence. Any AI-enabled workflow should be piloted, independently evaluated, and governed through privacy, equity, and clinical-safety controls.

Evidence Synthesis Focuses on Clinical Guidance and Program Delivery

This executive summary is based on a structured interpretation of established maternal-immunization principles, including passive antibody transfer, antenatal-care integration, vaccine confidence, access, supply continuity, safety monitoring, and health-information interoperability. The analysis organizes implications across the specified regions, country groups, and countries. It does not provide market estimates, market shares, forecasts, or company-level assessments. Country and group observations are framed as implementation considerations rather than claims of identical policy or coverage.

Sustained Newborn Protection Depends on Reliable Antenatal Delivery

Maternal pertussis vaccination is most effective as a coordinated component of prenatal and infant immunization systems. The central priorities are timely recommendation and administration, equitable access, trusted counseling, dependable supply, high-quality records, and continuous safety surveillance. Regional and country programs can improve outcomes by adapting these principles to local care pathways while using responsible digital and AI tools to identify gaps and support follow-up.

Product Code: MRR-1F6B55428628

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Maternal Pertussis Vaccine for Newborn Protection Market, by Vaccine Type

7.1. Introduction
7.2. Adsorbed Tdap
7.3. Non Aluminum Adjuvanted Tdap

8. Maternal Pertussis Vaccine for Newborn Protection Market, by Dosage Form

8.1. Introduction
8.2. Multi Dose
8.3. Single Dose

9. Maternal Pertussis Vaccine for Newborn Protection Market, by Application

9.1. Introduction
9.2. Maternal Immunization Programs
9.3. Routine Immunization

10. Maternal Pertussis Vaccine for Newborn Protection Market, by Administration Setting

10.1. Introduction
10.2. Inpatient
- 10.2.1. Private Hospitals
- 10.2.2. Public Hospitals
10.3. Outpatient
- 10.3.1. Community Clinics
- 10.3.2. Home Healthcare

11. Maternal Pertussis Vaccine for Newborn Protection Market, by Route of Administration

11.1. Introduction
11.2. Intramuscular Injection
11.3. Subcutaneous Injection

12. Maternal Pertussis Vaccine for Newborn Protection Market, by Age Group

12.1. Introduction
12.2. 18-24 Years
12.3. 25-34 Years
12.4. 35-44 Years

13. Maternal Pertussis Vaccine for Newborn Protection Market, by End User

13.1. Introduction
13.2. Ambulatory Care Centers
- 13.2.1. Ambulatory Surgical Centers
- 13.2.2. Physician Offices
13.3. Clinics
- 13.3.1. General Clinics
- 13.3.2. Specialized Clinics
13.4. Hospitals
- 13.4.1. Private Hospitals
- 13.4.2. Public Hospitals

14. Maternal Pertussis Vaccine for Newborn Protection Market, by Distribution Channel

14.1. Introduction
14.2. Hospital Pharmacies
- 14.2.1. Affiliated Hospital Pharmacies
- 14.2.2. Independent Hospital Pharmacies
14.3. Online Pharmacies
- 14.3.1. Direct To Consumer
- 14.3.2. E Pharmacy Platforms
14.4. Retail Pharmacies
- 14.4.1. Chain Pharmacies
- 14.4.2. Independent Pharmacies

15. Maternal Pertussis Vaccine for Newborn Protection Market, by Region

15.1. Introduction
15.2. Asia-Pacific
15.3. North America
15.4. Latin America
15.5. Europe
15.6. Middle East
15.7. Africa

16. Maternal Pertussis Vaccine for Newborn Protection Market, by Group

16.1. Introduction
16.2. ASEAN
16.3. GCC
16.4. European Union
16.5. BRICS
16.6. G7
16.7. NATO

17. Maternal Pertussis Vaccine for Newborn Protection Market, by Country

17.1. Introduction
17.2. United States
17.3. Canada
17.4. Mexico
17.5. Brazil
17.6. United Kingdom
17.7. Germany
17.8. France
17.9. Russia
17.10. Italy
17.11. Spain
17.12. China
17.13. India
17.14. Japan
17.15. Australia
17.16. South Korea

18. Competitive Landscape

18.1. Market Share Analysis, 2025
18.2. Market Concentration Analysis, 2025
- 18.2.1. Concentration Ratio (CR)
- 18.2.2. Herfindahl Hirschman Index (HHI)
18.3. Recent Developments & Impact Analysis, 2025
18.4. Product Portfolio Analysis, 2025
18.5. Benchmarking Analysis, 2025

19. Company Profiles

19.1. AJ Vaccines A/S
19.2. Astellas Pharma
19.3. Bharat Biotech
19.4. Biological E. Ltd.
19.5. Chongqing Zhifei Biological Products Co., Ltd.
19.6. GlaxoSmithKline (GSK) plc
19.7. MassBiologics
19.8. Meiji Holdings Co. Ltd.
19.9. Merck & Co., Inc.
19.10. Mitsubishi Tanabe Pharma Corporation
19.11. Panacea Biotec Ltd.
19.12. Sanofi
19.13. Serum Institute of India Pvt. Ltd.
19.14. Walvax Biotechnology Co., Ltd.

20. Key Experts